Last updated: 2026-10-19 18:02:20. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Geron Corp. (GERN) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $1.20, with a market capitalization of $751.69M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.04 to $2.01. This page covers its latest market performance, valuation, price trends and company information.
$751.69M | |
$1.20 | |
$16.80 | |
$0.75 | |
$1.17 | |
2.76M | |
9.91M | |
-- | |
$2.01 | |
$1.04 | |
-- | |
-- |
Geron Corp. (GERN) is currently trading at $1.20 as of 2026-10-19 18:01:00, up 2.14% ($0.03) from the previous close of $1.17
During today's regular trading session, GERN has traded between $0.75 and $16.80, with a trading volume of 2.76M shares. The current price is near the lower end of today's range.
Over the past seven days, Geron Corp. (GERN) moved from $1.22 to $1.20, representing a decline of 2.05% ($0.02).
The stock traded between $1.17 and $1.26 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 6.06 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 16.0%
GERN is currently trading at $1.20, placing it 16.0% of the way from its 52-week low of $1.04 to its 52-week high of $2.01. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 258 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Geron Corp. (GERN) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.